Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-3201b in Subjects With Lymphomas
NCT02732275Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of valemetostat in non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities at 28 days, Maximum concentration at 28 days and 10 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02732275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732275.